Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody, in monotherapy and in combination with the anti-PD-1 tislelizumab in patients with advanced solid tumors

Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody, in monotherapy and in combination with the anti-PD-1 tislelizumab in patients with advanced solid tumors